Ghazi et al Bressler SB, Bressler NM, Fine SL, et al. 1983. Subfoveal neovascular membranes in senile macular degeneration. Relationship between membrane size and visual prognosis. Retina, 3:7–11. Busquets MA, Shah GK, Wickens J, et al. 2003. Ocular photodynamic therapy with verteporﬁn for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina, 23:299–306. Ergun E, Maar N, Radner W, et al. 2003. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age- related macular degeneration. Ophthalmology, 110:65–9. Ferris III FL, Fine SL, Hyman L. 1984. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol, 102:1640–2. Fletcher DC, Schuchard RA. 1997. Preferred retinal loci: relationship to macular scotomas in a low-vision population. Ophthalmology, 104:632–8. Gass JDM. 1967a. Pathogenesis of disciform detachment of the neuroepithelium. III. Senile disciform macular degeneration. Am J Ophthalmol, 63:617–44. Gass JDM. 1967b. Pathogenesis of disciform detachment of the neuroepithelium. IV. Fluorescein angiographic study of senile disciform macular degeneration. Am J Ophthalmol, 63:645–59. Ghazi NG, Jabbour NM, De La Cruz ZC, et al. 2001. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina, 21:478–86. Green WR, Enger C. 1993. Age-related macular degeneration histopatho- logic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology, 100:1519–35. Green WR, Key 3rd SN. 1977. Senile macular degeneration: a histopatho- logic study. Trans Am Ophthalmol Soc, 75:180–254. Ishibashi T, Inomata H, Sakamoto T, et al. 1995. Pericytes of newly formed vessels in experimental subretinal neovascularization. Arch Ophthalmol, 113:227–31. Ishibashi T, Ryan SJ. 1992. Maturation of newly-formed subretinal vessels. EXS, 61:59–63. Klein R, Wang Q, Klein BE, et al. 1995. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci, 36:182–91. [MPSG] Macular Photocoagulation Study Group. 1993. Laser photoco- agulation of subfoveal neovascular lesions of age-related macular degeneration. Arch Ophthalmol, 111:1200–9. Margherio RR, Margherio AR, DeSantis ME. 2000. Laser treatment with verteporﬁn therapy and its potential impact on retinal practices. Retina, 20:325–30. Michels S, Barbazetto I, Schmidt-Erfurth U. 2000. Choroidal changes after photodynamic therapy (PDT). A two year follow-up study of 38 patients. Klin Monatsbl Augenheilkd, 217:94–9. Midena E, Radin PP, Pilotto E, et al. 2004. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry study. Semin Ophthalmol, 19:55–61. Olk RJ, Burgess DB, McCormick PA. 1984. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology, 91:1592–602. Royster AJ, Nanda SK, Hatchell DL, et al. 1988. Photochemical initiation of thrombosis. Fluorescein angiographic, histologic, and ultrastructural alterations in the choroid, retinal pigment epithelium and retina. Arch Ophthalmol, 106:1608–14. Saperstein DA, Rosenfeld PJ, Bressler NM, et al; Verteporﬁn in Ocular Histoplasmosis (VOH) Study Group. 2002. Photodynamic therapy of subfoveal choroidal neovascularization with verteporﬁn in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospec- tive case series. Ophthalmology, 109:1499–505. Schmidt-Erfurth U. 1999. Indocyanine green angiography and retinal sensitivity after photodynamic therapy of subfoveal choroidal neovas- cularization. Semin Ophthalmol, 14:35–44. Schmidt-Erfurth UM, Elsner H, Terai N, et al. 2004. Effects of verteporﬁn therapy on central visual ﬁeld function. Ophthalmology, 111:931–9. Schuchard RA, Fletcher DC. 2000. Preferred retinal locus and the scanning laser ophthalmoscope. In: Albert DM, Jacobiec FA (eds). Principles and practice of ophthalmology. St. Lowis: WB Saunders Company, 2nd Edition, Vol. 2, Ch. 395:5438–43. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. 2000. A prelimi- nary study of photodynamic therapy using verteporﬁn for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. Arch Ophthalmol, 118:327–36. Soubrane G, Coscas GJ. 2001. Choroidal neovascularization in degenerative myopia. In: Ryan SJ, Wilkinson CP (eds). Retina. St. Lowis: Mosby, 3rd Edition, Vol. 2, Ch. 67:1136–52. Sunness JS, Applegate CA, Haselwood D, et al. 1996. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology, 103:1458–66. Suzuki H, Yoshida K. 1998. Electron microscopic study of capillary in the human renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi, 89:14–22. Teeters VW, Bird AC. 1973. A clinical study of the vascularity of senile disciform macular degeneration. Am J Ophthalmol, 75:53–65. Timberlake GT, Mainster MA, Peli E, et al. 1986. Reading with a macular scotoma. I. Retinal location of scotoma and ﬁxation area. Invest Ophthalmol Vis Sci, 27:1137–47. Timberlake GT, Peli E, Essock EA, et al. 1987. Reading with a macular scotoma. II. Retinal locus for scanning text. Invest Ophthalmol Vis Sci, 28:1268–74. [TAP] Treatment of Age-Related Macular Degeneration With Photody- namic Therapy Study Group. 1999. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporﬁn: one-year results of 2 randomized clinical trials – TAP Report 1. Arch Ophthalmol, 117:1329–45. [VIP] Verteporfin in Photodynamic Therapy Study Group. 2001a. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporﬁn. 1-year results of a randomized clinical trial – VIP report no. 1. Ophthalmology, 108:841–52. [VIP] Verteporfin In Photodynamic Therapy Study Group. 2001b. Verteporﬁn therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy (VIP) report 2. Am J Ophthalmol, 131:541–60. [VIP] Verteporﬁn Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporﬁn In Photodynamic Therapy (VIP) Study Group Principal Investigators. 2002. Guidelines for using verteporﬁn (Visudyne® ) in photodynamic therapy to treat choroidal neovascularization secondary to age-related macular degen- eration and other causes. Retina, 22:6–18. Varano M, Parisi V, Tedeschi M, et al. 2005. Macular function after PDT in myopic maculopathy: psychophysical and electrophysiological evalu- ation. Invest Ophthalmol Vis Sci, 46:1453–62. von Noorden GK, Mackensen G. 1962. Phenomenology of eccentric ﬁxa- tion. Am J Ophthalmol, 53:642–61. Whittaker SG, Budd J, Cummings RW. 1988. Eccentric ﬁxation with macular scotoma. Invest Ophthalmol Vis Sci, 29:268–78. Yannuzzi LA, Negrao S, Iida T, et al. 2001. Retinal angiomatous prolifera- tion in age-related macular degeneration. Retina, 21:416–34. Yodoi Y, Tsujikawa A, Kameda T, et al. 2007. Central retinal sensi- tivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol, 143:984–94. 780 Clinical Ophthalmology 2008:2(4)